Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Summary

This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer. The research team also want to know whether what they see on PET/CT images represents the tumor tissue being excised from the patient's body. The research team is also interested to investigate another new imaging technique called PSMA PET/CT. Participants will be invited to undergo another PET/CT scan, with the PSMA tracer (68Ga-PSMA-11). This is not required but just an option for volunteer patients. Patients who have not received an 18F-FDG PET/CT within one month of enrollment will also undergo an FDG PET/CT scan. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, 68Ga-PSMA-11 and 68Ga-FAPi, and 18F-FDG (if applicable). Because some cancers take up 68Ga-PSMA-11 and/or 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs where it occurs in patient's body. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers. PSMA stands for Prostate Specific Membrane Antigen. This name is incorrect as PSMA is also found in many other cancers. The function of PSMA is not well understood but imaging studies have shown that PSMA can be detected with PET in many non-prostate cancers. Imaging FAP with PET/CT may in the future provide additional information about various cancers.

Conditions

• Breast Carcinoma
• Colon Carcinoma
• Esophageal Carcinoma
• Gastric Carcinoma
• Head and Neck Carcinoma
• Kidney Carcinoma
• Lung Carcinoma
• Ovarian Carcinoma
• Pancreatic Carcinoma
• Solid Neoplasm
• Uterine Corpus Cancer

Interventions

PROCEDURE

Computed Tomography

Undergo PET/CT scan

RADIATION

Gallium Ga 68 FAPi-46

Given IV

RADIATION

Gallium Ga 68-labeled PSMA-11

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scan

RADIATION

18F-FDG

Given IV

Sponsors & Collaborators

• Society of Nuclear Medecine and Molecular Imaging

  collaborator UNKNOWN

• Jonsson Comprehensive Cancer Center

  lead OTHER

Principal Investigators

• Jeremie Calais, MD · UCLA / Jonsson Comprehensive Cancer Center

Study Design

Allocation

NA

Purpose

BASIC_SCIENCE

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-11-05

Primary Completion

2030-06-01

Completion

2031-10-17

FDA Drug

Yes

FDA Device

Yes

Countries

• United States

Study Locations